Trial Profile

The effects of TNF blockade (using etanercept) on substrates of mood and cognition in patients with inflammatory arthritis.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary)
Indications Psoriatic arthritis
Focus Adverse reactions
Acronyms SPECT

Most Recent Events

08 Oct 2014 Accrual to date is 86% according to United Kingdom Clinical Research Network record
08 Oct 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network .
21 Jun 2012 United Kingdom Clinical Research Network reports accrual to date changed from 83% to 86%.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com